ArticleUnited European gastroenterology journal2025
Burden of Alcohol-Related Liver Disease and Alcohol Use Disorder in Asia.
Article in United European gastroenterology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Preclinical Analysis of Bone Marrow-Derived Stem Cell Therapy Response and Transcriptomic Overlap Analysis in a Severe Alcoholic Hepatitis Mouse Model.Gut and liver · 2026Pooled it
- An Attention-Residual Hybrid CNN for CT-Based Multiclass Classification of Alcohol-Related Liver Disease: Differential Diagnosis Against HBV-Related Cirrhosis.Diagnostics (Basel, Switzerland) · 2026Article
- Comment on "Compositional and Metabolomic Shifts of the Gut Microbiome in Alcohol-Related Liver Disease".Journal of gastroenterology and hepatology · 2026Article
- Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study.Hepatology international · 2026Review
- Longitudinal Inpatient Trajectories After Splenic Artery Embolization in Cirrhosis: Real-World Evidence from Kazakhstan.Journal of clinical medicine · 2026Article
- Prevalence, Clinical Profiles, Disease Severity, and Patient Outcomes of Alcoholic Liver Disease in a Tertiary Care Hospital of Nepal.Health science reports · 2026Article
- Unveiling the Immunopharmacological Mechanisms of Biejiajian Pills (BJJP) Underlying the Treatment of Hepatic Fibrosis: Insights From Network Pharmacology and Experimental Validation.Food science & nutrition · 2026Article
- Spatial characterization of intrahepatic fat deposition across steatotic liver disease subcategories: a multicenter study.BMC medicine · 2026Article
- Rising burden of steatotic liver disease in women of childbearing age and projections to 2035.JHEP reports : innovation in hepatology · 2026Article
- Burden of Alcohol-Related Liver Disease and Alcohol Use Disorder in Asia.United European gastroenterology journal · 2025Article
- Alcohol-Associated Hepatitis: Translating Pathophysiology into Targeted Clinical Trials.Current hepatology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundAs alcohol consumption continues to rise rapidly in Asia, research into its significant consequences, alcohol-related liver disease (ALD), and alcohol use disorder (AUD) is still limited.
objectiveThis study examines the burden of alcohol-related liver disease and alcohol use disorder in Asia from 2000 to 2021.
methodsWe analyzed data from the global burden of disease (GBD) Study 2021 to assess age-standardized prevalence, incidence, and mortality rates for alcohol-related liver disease and alcohol use disorder in Asia from 2000 to 2021.
resultsIn 2021, there were approximately 1.40 million cases of ALD, resulting in 175,370 deaths and 53.18 million cases of AUD, with 57,110 deaths. Asia accounted for 46.35% of the global prevalence of ALD (an increase of 6.87% since 2000) and 47.86% of the global prevalence of AUD (an increase of 0.82% since 2000). A 91.2% increase in crude ALD prevalence, incidence, and mortality from 2000 to 2021 in Asia was observed. South Asia exhibited the highest crude burden of ALD, while Central Asia had the highest age-standardized rate. Notably, ALD prevalence increased in South Asia (Annual Percent Change [APC]: 0.10%, 95% CI: 0.08-0.13) and Central Asia (APC: 0.88%, 95% CI: 0.79-0.97), even as other regions experienced declines.
conclusionsThis study reveals a disproportionately increasing burden of ALD and AUD in Asia compared with global trends, with significant variability across subregions. Central and South Asia are identified as the primary drivers of the burden associated with ALD and AUD in this region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.